Mallinckrodt (MNK) Presents New Data on TERLIVAZ Jan 22, 2024 06:53AM
Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress Jan 22, 2024 06:52AM
Mallinckrodt (MNK) Reports its Plan and the Scheme of Arrangement Became Effective, Debtors Emerged from the Chapter 11 Cases Nov 15, 2023 07:38AM
Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11 Nov 14, 2023 06:05PM
Mallinckrodt to Present Breadth of Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) Nov 8, 2023 06:45AM


Nov 7, 2023 06:00AM Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results
Nov 1, 2023 06:45AM Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meetin
Oct 26, 2023 06:53AM Mallinckrodt (MNKTQ) Presents Latest Health Economics Data on Acthar Gel
Oct 26, 2023 06:53AM Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023
Oct 22, 2023 03:05PM Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting
Oct 10, 2023 01:50PM Mallinckrodt (MNKTQ) Receives US Court Approval for Financial Restructuring Plan
Oct 10, 2023 01:49PM Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan
Aug 31, 2023 06:45AM Mallinckrodt (MNKTQ) Granted U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules
Aug 31, 2023 06:45AM Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
Aug 30, 2023 11:54AM Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations